- Home
- KNSL vs ACLX Comparison
KNSL vs ACLX Comparison
Compare KNSL & ACLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | KNSL | ACLX |
|---|---|---|
| Founded | 2009 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Property-Casualty Insurers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 8.3B | 6.7B |
| IPO Year | 2016 | 2022 |
Fundamental Metrics
Financial Performance| Metric | KNSL | ACLX |
|---|---|---|
| Price | $327.51 | $115.12 |
| Analyst Decision | Hold | Hold |
| Analyst Count | 11 | 15 |
| Target Price | ★ $403.45 | $115.85 |
| AVG Volume (30 Days) | 237.3K | ★ 783.3K |
| Earning Date | 04-23-2026 | 05-06-2026 |
| Dividend Yield | ★ 0.31% | N/A |
| EPS Growth | ★ 21.77 | N/A |
| EPS | ★ 4.88 | N/A |
| Revenue | ★ $1,873,987,000.00 | $22,286,000.00 |
| Revenue This Year | $5.60 | $342.39 |
| Revenue Next Year | $7.88 | $170.71 |
| P/E Ratio | $70.35 | ★ N/A |
| Revenue Growth | ★ 18.04 | N/A |
| 52 Week Low | $321.97 | $47.86 |
| 52 Week High | $512.76 | $115.13 |
Technical Indicators
Market Signals| Indicator | KNSL | ACLX |
|---|---|---|
| Relative Strength Index (RSI) | 34.58 | 80.04 |
| Support Level | $321.97 | $63.46 |
| Resistance Level | $364.61 | N/A |
| Average True Range (ATR) | 11.64 | 0.10 |
| MACD | -1.18 | -0.62 |
| Stochastic Oscillator | 13.65 | 94.60 |
Price Performance
Historical ComparisonAbout KNSL Kinsale Capital Group Inc.
Kinsale Capital Group Inc is an insurance holding company. The company is engaged in offering property, casualty, and specialty insurance products. It offers specialty insurance products for allied health, healthcare, life sciences, professional, and a public entity. The company operates in only one reportable segment which is the Excess and Surplus Lines Insurance segment, which includes commercial excess and surplus lines liability and property insurance products through its underwriting divisions. The company generates revenues in the form of premiums and investment income.
About ACLX Arcellx Inc.
Arcellx Inc a clinical-stage biotechnology company reimagining cell therapy through the development of immunotherapies for patients with cancer and other incurable diseases. Its pipeline includes Multiple Myeloma, Acute Myeloid Leukemia, Non-Oncology, and Solid Tumors.